Other Events ·
Moleculin Biotech reports positive preliminary efficacy results from first 45 patients in Phase 2/3 MIRACLE trial
MBRXMoleculin Biotech, Inc.
Moleculin Biotech, Inc. announced positive preliminary unblinded efficacy results from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial. The Annamycin treatment arms showed favorable efficacy trends compared to the control arm in patients with relapsed or refractory acute myeloid leukemia (R/R AML). Moleculin Biotech, Inc. is a biotechnology company focused on developing therapeutic solutions for hematologic malignancies.